Dr. Samuel N. Lederman, M.D.
OB-GYN (Obstetrics & Gynecology) (Obstetrics & Gynecology Physician)
- Medicare participating
At a glance
- Medical school
- University of Miami, Lm Miller School of Medicine (1987)
- Years since graduation
- 39
- In the NPI registry since
- 2006
- Medicare patients seen, 2024
- 184
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 1987Medical school: University of Miami, Lm Miller School of Medicine
- 2006Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Obstetrics & Gynecology Physician primary
FL license ME60019
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Map: OB-GYN (Obstetrics & Gynecology) per capita by county →
Where they work
Hospitals
- Jupiter Medical Center Jupiter, FL
- Good Samaritan Medical Center West PAlm Beach, FL
Medical groups
- Womens Care Florida LLC (325 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 184
- Services billed
- 542
- Patients’ average age
- 72
| Service | Times | Patients |
|---|---|---|
| Established patient office or other outpatient visit, 20-29 minutes | 92 | 59 |
| Cervical or vaginal cancer screening; pelvic and clinical breast examination | 82 | 82 |
| Screening 3d breast mammography | 62 | 62 |
| Screening mammography | 61 | 61 |
| Screening papanicolaou smear; obtaining, preparing and conveyance of cervical or vaginal smear to laboratory | 40 | 40 |
| Ultrasound scan of uterus, ovaries, tubes, cervix and pelvic area through vagina | 28 | 21 |
| Stool analysis for blood to screen for colon tumors | 26 | 26 |
| New patient office or other outpatient visit, 30-44 minutes | 19 | 19 |
| Biopsy of lining of uterus | 12 | 12 |
| Established patient office or other outpatient visit, 30-39 minutes | 11 | 11 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Estradiol Other prescribers in Lake Worth, FL | 229 |
| Progesterone (progesterone, micronized) Other prescribers in Lake Worth, FL | 52 |
| Valacyclovir (valacyclovir hcl) Other prescribers in Lake Worth, FL | 37 |
| Estradiol (Twice Weekly) (estradiol) Other prescribers in Lake Worth, FL | 28 |
| Alendronate Sodium Other prescribers in Lake Worth, FL | 27 |
| Raloxifene Hcl Other prescribers in Lake Worth, FL | 27 |
| Myrbetriq (mirabegron) Other prescribers in Lake Worth, FL | 24 |
| Terconazole | 19 |
| Fluconazole Other prescribers in Lake Worth, FL | 17 |
| Microgestin (norethindrone ac/eth estradiol) | 17 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 12 companies reported 42 payments worth $7,111 in total to this clinician.
| Astellas Pharma US Inc | $4,179 |
|---|---|
| Bayer HealthCare Pharmaceuticals Inc. | $2,315 |
| Sumitomo Pharma America, Inc. | $148 |
| Mayne Pharma Commercial LLC | $117 |
| Astellas Pharma Global Development | $105 |
| Lsi Solutions Inc | $50.78 |
| Hologic Sales and Service, LLC | $45.00 |
| Exeltis, USA Inc. | $39.58 |
| Compensation for services other than consulting (speaking, faculty) | $5,872 |
|---|---|
| Food and Beverage | $1,198 |
| Travel and Lodging | $41.42 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Astellas Pharma US Inc Oct 29, 2025 | Compensation for services other than consulting (speaking, faculty) Veozah · Biological | $2,575 |
| Bayer HealthCare Pharmaceuticals Inc. Dec 10, 2025 | Compensation for services other than consulting (speaking, faculty) Lynkuet · Womens Health | $2,009 |
| Astellas Pharma US Inc Nov 28, 2025 | Compensation for services other than consulting (speaking, faculty) Veozah · Biological | $773 |
| Astellas Pharma US Inc Mar 12, 2025 | Compensation for services other than consulting (speaking, faculty) Veozah · Biological | $515 |
| Astellas Pharma US Inc Oct 29, 2025 | Travel and Lodging Veozah · Biological · travel to Boca Raton, FL | $41.42 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 18 industry-funded studies in 2025, from 13 companies. The companies reported $2,970,220 in research payments for these studies, mostly to the institutions running them.
- A Study to Investigate Weight Management With Bimagrumab (LY3985863) and Tirzepatide (LY3298176), Alone or in Combination, in Adults With Obesity or Overweight
Eli Lilly and Company · Active, not recruiting · NCT06643728 - Study name not reported
Roche Molecular Systems, Inc. - A Phase IV, Longitudinal, Observational Study Examining Real-World Outcomes of Non-Hormonal Pharmacotherapies Among Individuals Treated for Bothersome Vasomotor Symptoms
Astellas Pharma Global Development - Study name not reported
Roche Molecular Systems, Inc. - Study name not reported
Roche Molecular Systems, Inc. - Study name not reported
Roche Molecular Systems, Inc. - A phase 3B, open-label, single-arm study in adolescent and adult femal
GlaxoSmithKline, LLC. - NB (Contrave) Cardiovascular Outcomes Trial
Currax Pharmaceuticals LLC - Study of the Safety and Contraceptive Efficacy of Relugolix Combination Therapy in Women With Uterine Fibroids or Endometriosis Who Are at Risk for Pregnancy
Sumitomo Pharma America, Inc. · Completed · NCT04756037 - A master protocol to investigate the efficacy and safety of orforglipron tablet once daily compared with placebo in female participants with stress urinary incontinence who have obesity or overweight (restrain-sui) ; …
Eli Lilly and Company
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.